Repurposing of compound libraries yields new inhibitors of NDM-1 metallo-β-lactamase with diverse zinc-binding moieties

Vid Kavaš , Philip Hinchliffe , Maša Zorman , Alen Krajnc , Matic Proj , Majda Golob , Martina Hrast Rambaher , James Spencer , Stanislav Gobec
{"title":"Repurposing of compound libraries yields new inhibitors of NDM-1 metallo-β-lactamase with diverse zinc-binding moieties","authors":"Vid Kavaš ,&nbsp;Philip Hinchliffe ,&nbsp;Maša Zorman ,&nbsp;Alen Krajnc ,&nbsp;Matic Proj ,&nbsp;Majda Golob ,&nbsp;Martina Hrast Rambaher ,&nbsp;James Spencer ,&nbsp;Stanislav Gobec","doi":"10.1016/j.ejmcr.2025.100282","DOIUrl":null,"url":null,"abstract":"<div><div>Antimicrobial resistance has emerged as a critical global public health threat, impacting human, animal and environmental health. An important mechanism of resistance is the production of β-lactamases, enzymes that hydrolyze the β-lactam ring, rendering β-lactam antibiotics ineffective. Metallo-β-lactamases (MBLs), which contain zinc ions in their active sites, are particularly challenging to counter as there are currently no inhibitors targeting these enzymes available on the market. Therefore, there is an urgent need for innovative drug discovery strategies to develop MBL-targeted therapies. New Delhi Metallo-β-Lactamase 1 (NDM-1) is the most widely disseminated MBL, with a global distribution in <em>Enterobacterales</em>. In this study, we used our library of fragment-sized chloroacetamides as a starting point to synthesize mercaptoacetamides as potential NDM-1 inhibitors. This resulted in a compound (<strong>14a</strong>) with an IC<sub>50</sub> of 20 μM, which crystallography shows binds to NDM-1 in two different poses. Using this structure as a starting point for <em>in silico</em> design, we developed a series of larger thiol-based compounds designed to occupy more space in the active site and to utilize other novel zinc-binding groups. Although some showed minimal inhibition (which makes them valuable as decoys for metalloenzyme studies) one compound exhibited an IC<sub>50</sub> of 14 μM, with crystallography indicating that an additional aromatic group, compared to <strong>14a</strong>, interacts with hydrophobic residues on an NDM-1 active site loop. These data identify promising scaffolds for the further development of potent MBL inhibitors and show the utility of repurposing chemical libraries to target clinically important enzymes.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100282"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277241742500038X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial resistance has emerged as a critical global public health threat, impacting human, animal and environmental health. An important mechanism of resistance is the production of β-lactamases, enzymes that hydrolyze the β-lactam ring, rendering β-lactam antibiotics ineffective. Metallo-β-lactamases (MBLs), which contain zinc ions in their active sites, are particularly challenging to counter as there are currently no inhibitors targeting these enzymes available on the market. Therefore, there is an urgent need for innovative drug discovery strategies to develop MBL-targeted therapies. New Delhi Metallo-β-Lactamase 1 (NDM-1) is the most widely disseminated MBL, with a global distribution in Enterobacterales. In this study, we used our library of fragment-sized chloroacetamides as a starting point to synthesize mercaptoacetamides as potential NDM-1 inhibitors. This resulted in a compound (14a) with an IC50 of 20 μM, which crystallography shows binds to NDM-1 in two different poses. Using this structure as a starting point for in silico design, we developed a series of larger thiol-based compounds designed to occupy more space in the active site and to utilize other novel zinc-binding groups. Although some showed minimal inhibition (which makes them valuable as decoys for metalloenzyme studies) one compound exhibited an IC50 of 14 μM, with crystallography indicating that an additional aromatic group, compared to 14a, interacts with hydrophobic residues on an NDM-1 active site loop. These data identify promising scaffolds for the further development of potent MBL inhibitors and show the utility of repurposing chemical libraries to target clinically important enzymes.

Abstract Image

对化合物文库的重新利用产生了具有不同锌结合部分的NDM-1金属β-内酰胺酶的新抑制剂
抗菌素耐药性已成为严重的全球公共卫生威胁,影响着人类、动物和环境健康。耐药的一个重要机制是β-内酰胺酶的产生,这种酶能水解β-内酰胺环,使β-内酰胺类抗生素失效。金属β-内酰胺酶(MBLs)在其活性位点含有锌离子,由于目前市场上没有针对这些酶的抑制剂,因此特别具有挑战性。因此,迫切需要创新的药物发现策略来开发mbl靶向治疗。新德里金属β-内酰胺酶1 (New Delhi metallic -β-Lactamase 1, NDM-1)是分布最广泛的MBL,在肠杆菌中具有全球分布。在本研究中,我们以片段大小的氯乙酰胺文库为起点,合成了巯基乙酰胺作为潜在的NDM-1抑制剂。这种方法得到了IC50为20 μM的化合物(14a),晶体学显示它以两种不同的姿态与NDM-1结合。利用这种结构作为硅设计的起点,我们开发了一系列更大的硫醇基化合物,旨在占据活性位点的更多空间,并利用其他新颖的锌结合基团。尽管一些化合物表现出最小的抑制作用(这使得它们作为金属酶研究的有价值的诱捕物),但其中一个化合物的IC50为14 μM,晶体学表明,与14a相比,另一个芳香基团与NDM-1活性位点环上的疏水残基相互作用。这些数据为进一步开发强效MBL抑制剂确定了有希望的支架,并显示了重新利用化学文库以靶向临床重要酶的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信